JPWO2021059136A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021059136A5 JPWO2021059136A5 JP2022518675A JP2022518675A JPWO2021059136A5 JP WO2021059136 A5 JPWO2021059136 A5 JP WO2021059136A5 JP 2022518675 A JP2022518675 A JP 2022518675A JP 2022518675 A JP2022518675 A JP 2022518675A JP WO2021059136 A5 JPWO2021059136 A5 JP WO2021059136A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- alkylene
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905532P | 2019-09-25 | 2019-09-25 | |
| US62/905,532 | 2019-09-25 | ||
| US202063021216P | 2020-05-07 | 2020-05-07 | |
| US63/021,216 | 2020-05-07 | ||
| US202063069831P | 2020-08-25 | 2020-08-25 | |
| US63/069,831 | 2020-08-25 | ||
| PCT/IB2020/058854 WO2021059136A1 (fr) | 2019-09-25 | 2020-09-22 | Modulateurs polyhétérocycliques de sting (stimulateur des gènes de l'interféron) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550297A JP2022550297A (ja) | 2022-12-01 |
| JPWO2021059136A5 true JPWO2021059136A5 (fr) | 2023-09-25 |
Family
ID=72744805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518675A Pending JP2022550297A (ja) | 2019-09-25 | 2020-09-22 | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210087180A1 (fr) |
| EP (1) | EP4034534A1 (fr) |
| JP (1) | JP2022550297A (fr) |
| KR (1) | KR20220070254A (fr) |
| CN (1) | CN114728946A (fr) |
| AU (1) | AU2020355343B2 (fr) |
| BR (1) | BR112022005463A2 (fr) |
| CA (1) | CA3155569A1 (fr) |
| CL (1) | CL2022000736A1 (fr) |
| CO (1) | CO2022003321A2 (fr) |
| CR (1) | CR20220126A (fr) |
| EC (1) | ECSP22022958A (fr) |
| GE (1) | GEP20237572B (fr) |
| IL (1) | IL291650A (fr) |
| MX (1) | MX2022003633A (fr) |
| PE (1) | PE20221784A1 (fr) |
| TW (2) | TW202244043A (fr) |
| UY (1) | UY38892A (fr) |
| WO (1) | WO2021059136A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022063205A1 (fr) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | Composé aryl formamide, son procédé de préparation et ses utilisations médicales |
| US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| US20220388986A1 (en) * | 2021-04-29 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2023222644A1 (fr) * | 2022-05-18 | 2023-11-23 | F. Hoffmann-La Roche Ag | Dérivés de pyrazole utilisés en tant qu'agonistes de sting |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US9040538B2 (en) | 2009-05-21 | 2015-05-26 | Universite Laval | Pyrimidines as novel therapeutic agents |
| PL2614082T3 (pl) | 2010-09-09 | 2019-02-28 | Pfizer Inc. | Cząsteczki wiążące 4-1BB |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN108473587A (zh) | 2016-01-25 | 2018-08-31 | 辉瑞公司 | 用于治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合 |
| SG11201808708RA (en) * | 2016-04-07 | 2018-11-29 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| CA3067257A1 (fr) * | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Modulateurs a petites molecules de sting humain |
| US20200399268A1 (en) * | 2018-02-16 | 2020-12-24 | UCB Biopharma SRL | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives |
| US10538542B2 (en) * | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
-
2020
- 2020-09-22 JP JP2022518675A patent/JP2022550297A/ja active Pending
- 2020-09-22 AU AU2020355343A patent/AU2020355343B2/en active Active
- 2020-09-22 CR CR20220126A patent/CR20220126A/es unknown
- 2020-09-22 CA CA3155569A patent/CA3155569A1/fr active Pending
- 2020-09-22 MX MX2022003633A patent/MX2022003633A/es unknown
- 2020-09-22 PE PE2022000465A patent/PE20221784A1/es unknown
- 2020-09-22 KR KR1020227013541A patent/KR20220070254A/ko not_active Application Discontinuation
- 2020-09-22 BR BR112022005463A patent/BR112022005463A2/pt unknown
- 2020-09-22 WO PCT/IB2020/058854 patent/WO2021059136A1/fr unknown
- 2020-09-22 EP EP20786063.6A patent/EP4034534A1/fr active Pending
- 2020-09-22 CN CN202080081716.2A patent/CN114728946A/zh active Pending
- 2020-09-22 GE GEAP202015908A patent/GEP20237572B/en unknown
- 2020-09-23 US US17/029,557 patent/US20210087180A1/en active Pending
- 2020-09-23 UY UY0001038892A patent/UY38892A/es unknown
- 2020-09-24 TW TW111103766A patent/TW202244043A/zh unknown
- 2020-09-24 TW TW109133180A patent/TWI757889B/zh active
-
2022
- 2022-03-23 CO CONC2022/0003321A patent/CO2022003321A2/es unknown
- 2022-03-23 IL IL291650A patent/IL291650A/en unknown
- 2022-03-24 EC ECSENADI202222958A patent/ECSP22022958A/es unknown
- 2022-03-24 CL CL2022000736A patent/CL2022000736A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hirte et al. | A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia | |
| US20040034026A1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| US20080193448A1 (en) | Combinations and Methods of Using an Indolinone Compound | |
| JP7361687B2 (ja) | グルタミナーゼ阻害薬療法 | |
| CN107148285A (zh) | 吡咯并苯并二氮杂*‑抗体缀合物 | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| US20180085341A1 (en) | Methods for treating cancer | |
| CN110072528B (zh) | 治疗肿瘤的药物组合物 | |
| US10646464B2 (en) | Methods for treating cancer | |
| AU2011240003A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| JP2020523355A (ja) | 肉腫を処置することへの使用のためのチノスタムスチン | |
| JP5599773B2 (ja) | リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体 | |
| JP2020515582A (ja) | 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート | |
| US20180250260A1 (en) | Methods for treating cancer | |
| Zhang et al. | ATG7-dependent and independent autophagy determine the type of treatment in lung cancer | |
| JP2022512826A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| JPWO2021059136A5 (fr) | ||
| EP1441714A2 (fr) | Combinaisons comprenant un inhibiteur selectif de la cyclooxygenase-2 | |
| JP5553767B2 (ja) | 新規で有用な下部尿路症状治療剤 | |
| JP2019519573A (ja) | がんを処置するための方法 | |
| JP7223998B2 (ja) | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 | |
| RU2754131C1 (ru) | Комбинированная терапия ингибитором ezh2 | |
| EP3806851A1 (fr) | Agents de mélanocortine destinés à être utilisés dans le traitement thérapeutique d'un mélanome, de tumeurs du tractus gastro-intestinal et d'un carcinome de la thyroïde | |
| WO2022102731A1 (fr) | Traitement du cancer par utilisation combinée d'un antagoniste d'ep4 et d'un inhibiteur de point de contrôle immunitaire | |
| KR102110454B1 (ko) | microRNA-550a-3-5p 및 항암제를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물 |